Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cytogen Corporation
Cytogen Reports First Quarter 2008 Financial Results
May 24th, 2008
Cytogen Corporation (NASDAQ: CYTO) reported its financial results for the first quarter of 2008. Cytogen reported a net loss of $5.9 million, or $0.16 per diluted share for the first quarter of 2008, compared to a net loss of $4.8 million, or $0.16 per diluted share, for the same period in 2007. Cytogen's financial results for 2007 were favorably impacted by a $3.9 million net litigation settlement with Advanced Magnetics. Product revenues, which were predominately comprised of sales of QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide), and CAPHOSOL(R), an advanced electrolyte solution for the treatment of oral...
Source: Law & Health Weekly (2008-05-24)
|
